Selmaj Krzysztof, Kobelt Gisela, Berg Jenny, Orlewska Ewa, Capsa Daniela, Dalén Johan
Medical University of Łódź, Łódź, Poland.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):130-142. doi: 10.1177/1352458517708666.
In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 European countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in 2015 Polish Zloty (PLN).
A total of 411 MS patients (mean age = 40 years) participated in Poland; 94% were below retirement age, and of these, 59% were employed. Employment was related to disability, and MS affected productivity for 85% of those working. Overall, 97% and 71% of patients experienced fatigue and cognition as important problems, respectively. Mean utility and total annual costs were 0.686 and 48,700 PLN at Expanded Disability Status Scale (EDSS) 0-3, 0.521 and 59,200 PLN at EDSS 4-6.5 and 0.208 and 81,600 PLN at EDSS 7-9, respectively. The average cost of a relapse was 3,900 PLN.
This study illustrates the burden of MS on Polish patients and provides current data that are important for developing health policies.
为了评估针对无法观察到终身成本和结果的多发性硬化症（MS）干预措施的价值，必须将结果数据与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个欧洲国家开展的横断面回顾性研究的一部分，收集了MS患者当前的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，按严重程度水平，以2015年波兰兹罗提（PLN）呈现描述性分析结果。
波兰共有411例MS患者（平均年龄 = 40岁）参与研究；94%低于退休年龄，其中59%有工作。就业情况与残疾有关，MS影响了85%在职患者的生产力。总体而言，分别有97%和71%的患者将疲劳和认知视为重要问题。在扩展残疾状态量表（EDSS）为0 - 3时，平均效用和年度总成本分别为0.686和48,700波兰兹罗提；在EDSS为4 - 6.5时，分别为0.521和59,200波兰兹罗提；在EDSS为7 - 9时，分别为0.208和81,600波兰兹罗提。一次复发的平均成本为3,900波兰兹罗提。
本研究说明了MS给波兰患者带来的负担，并提供了对制定卫生政策很重要的当前数据。
